MESO Q4 2020 Earnings — Mesoblast Limited Revenue & Financial Results | Market Cap Arena

MESOMesoblast Limited

$2B

Q4 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$692,000-64.8% YoY

Gross Profit

-$24M-3529.9% margin

Operating Income

-$32M-4622.7% margin

Net Income

-$33M-4712.4% margin

EPS (Diluted)

$-0.60

QoQ Revenue Growth

-94.3%

Cash Flow

Operating Cash Flow

-$20M

Free Cash Flow

-$20M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$734M

Total Liabilities

$184M

Stockholders' Equity

$549M

Cash & Equivalents

$129M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$692,000	$2M	-64.8%
Gross Profit	-$24M	-$60M	+59.5%
Operating Income	-$32M	-$18M	-82.3%
Net Income	-$33M	-$21M	-57.3%